Aside from minor discomfort at the injection site in two cases, peripheral edema in four cases, pruritus in one patient, and fever in two cases, no other side effects were observed, and, in particular, there was no evidence of any systemic effects of VEGF on the development of retinopathy or new tumor growth in long-term follow-up. The gene discussed is VEGFA; the disease is retinal disorder.